197 related articles for article (PubMed ID: 36713431)
21. Expression of excision repair cross-complementation group 1 in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy.
Shen C; Chen L; Fu J; Lin H
J Cancer Res Ther; 2016 Oct; 12(Supplement):72-75. PubMed ID: 27721259
[TBL] [Abstract][Full Text] [Related]
22. Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression.
Usanova S; Piée-Staffa A; Sied U; Thomale J; Schneider A; Kaina B; Köberle B
Mol Cancer; 2010 Sep; 9():248. PubMed ID: 20846399
[TBL] [Abstract][Full Text] [Related]
23. Relationship between clinical toxicities and ERCC1 rs3212986 and XRCC3 rs861539 polymorphisms in cervical cancer patients.
Soares S; Nogueira A; Coelho A; Assis J; Pereira D; Bravo I; Medeiros R
Int J Biol Markers; 2018 Jan; 33(1):116-123. PubMed ID: 28708208
[TBL] [Abstract][Full Text] [Related]
24. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.
Friboulet L; Olaussen KA; Pignon JP; Shepherd FA; Tsao MS; Graziano S; Kratzke R; Douillard JY; Seymour L; Pirker R; Filipits M; André F; Solary E; Ponsonnailles F; Robin A; Stoclin A; Dorvault N; Commo F; Adam J; Vanhecke E; Saulnier P; Thomale J; Le Chevalier T; Dunant A; Rousseau V; Le Teuff G; Brambilla E; Soria JC
N Engl J Med; 2013 Mar; 368(12):1101-10. PubMed ID: 23514287
[TBL] [Abstract][Full Text] [Related]
25. [Effect of TUBB3, TS and ERCC1 mRNA expression on chemoresponse and clinical outcome of advanced gastric cancer by multiplex branched-DNA liquid chip technology].
Huang J; Hu H; Xie Y; Tang Y; Liu W; Zhong M
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Jun; 38(6):582-9. PubMed ID: 23828702
[TBL] [Abstract][Full Text] [Related]
26. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
Booton R; Ward T; Ashcroft L; Morris J; Heighway J; Thatcher N
J Thorac Oncol; 2007 Oct; 2(10):902-6. PubMed ID: 17909351
[TBL] [Abstract][Full Text] [Related]
27. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells.
Britten RA; Liu D; Tessier A; Hutchison MJ; Murray D
Int J Cancer; 2000 Sep; 89(5):453-7. PubMed ID: 11008208
[TBL] [Abstract][Full Text] [Related]
28. Prognostic and predictive role of ERCC1 protein expression in locally advanced stage III non-small cell lung cancer.
Sad LM; Younis SG; Elity MM
Med Oncol; 2014 Jul; 31(7):58. PubMed ID: 24935625
[TBL] [Abstract][Full Text] [Related]
29. Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy.
Kim KH; Do IG; Kim HS; Chang MH; Kim HS; Jun HJ; Uhm J; Yi SY; Lim DH; Ji SH; Park MJ; Lee J; Park SH; Kwon GY; Lim HY
APMIS; 2010 Dec; 118(12):941-8. PubMed ID: 21091775
[TBL] [Abstract][Full Text] [Related]
30. ERCC1 (excision repair cross-complementation group 1) expression as a predictor for response of neoadjuvant chemotherapy for FIGO stage 2B uterine cervix cancer.
Park JS; Jeon EK; Chun SH; Won HS; Lee A; Hur SY; Lee KH; Bae SN; Yoon SC; Hong SH
Gynecol Oncol; 2011 Feb; 120(2):275-9. PubMed ID: 21093896
[TBL] [Abstract][Full Text] [Related]
31. High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area.
Chiu TJ; Chen CH; Chien CY; Li SH; Tsai HT; Chen YJ
J Transl Med; 2011 Mar; 9():31. PubMed ID: 21426588
[TBL] [Abstract][Full Text] [Related]
32. Low expression of excision repair cross-complementation group-1 protein predicts better outcome in patients with locally advanced nasopharyngeal cancer treated with concurrent chemoradiotherapy.
Zhang Z; Jiang C; Hu L
Tumori; 2014; 100(3):328-32. PubMed ID: 25076246
[TBL] [Abstract][Full Text] [Related]
33. ERCC1 and topoisomerase I expression in small cell lung cancer: prognostic and predictive implications.
Sereno M; Cejas P; Moreno V; Belda-Iniesta C; López R; Nistal M; Feliu J; De Castro Carpeño J
Int J Oncol; 2012 Jun; 40(6):2104-10. PubMed ID: 22344449
[TBL] [Abstract][Full Text] [Related]
34. The age-related expression decline of ERCC1 and XPF for forensic age estimation: A preliminary study.
Deng XD; Gao Q; Zhang W; Zhang B; Ma Y; Zhang LX; Muer C; Xie Y; Liu Y
J Forensic Leg Med; 2017 Jul; 49():15-19. PubMed ID: 28486142
[TBL] [Abstract][Full Text] [Related]
35. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
Handra-Luca A; Hernandez J; Mountzios G; Taranchon E; Lacau-St-Guily J; Soria JC; Fouret P
Clin Cancer Res; 2007 Jul; 13(13):3855-9. PubMed ID: 17606717
[TBL] [Abstract][Full Text] [Related]
36. Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population.
Qi YJ; Cui S; Yang YZ; Han JQ; Cai BJ; Sheng CF; Ma Y; Wuren T; Ge RL
J Cancer Res Ther; 2013; 9(3):410-5. PubMed ID: 24125975
[TBL] [Abstract][Full Text] [Related]
37. Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy.
Huang PY; Li Y; Mai HQ; Luo RZ; Cai YC; Zhang L
Oral Oncol; 2012 Oct; 48(10):964-968. PubMed ID: 22571922
[TBL] [Abstract][Full Text] [Related]
38. The ERCC1 and ERCC4 (XPF) genes and gene products.
Manandhar M; Boulware KS; Wood RD
Gene; 2015 Sep; 569(2):153-61. PubMed ID: 26074087
[TBL] [Abstract][Full Text] [Related]
39. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS
Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544
[TBL] [Abstract][Full Text] [Related]
40. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
Olaussen KA; Mountzios G; Soria JC
Curr Opin Pulm Med; 2007 Jul; 13(4):284-9. PubMed ID: 17534174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]